There are total nine formulations were prepared and evaluated for various parameters. Formulation B9 containing L-HPC in concentration of 10% showed minimum disintegration time, wetting time as compare to other formulations. Results of dissolution studies showed that total drug was released in 6 min. The results shown that disintegration time was increased in the manners of L-HPC< crospovidone< croscarmellose sodium. 
Mefenamic acid, N-(2,3-xylyl)-2-aminobenzoic acid, is an analgesic used for the treatment of arthritic pain. Some of the spectrophotometric estimation methods include conversion to its colored iron complex [1] . The derivatization of aromatic ring by using coupling reaction with diazotized 4-amino-3,5-dinitrobenzoic acid has been performed prior to photometric estimation of mefenamic acid [2] . Spectrophotometric methods have been developed for the simultaneous estimation of mefenamic acid and paracetamol [3, 4] , mefenamic acid and ethamsylate [5, 6] and mefenamic acid and drotaverine hydrochloride [7] in combination drugs. Mefenamic acid has a strong absorption band at 353 nm with high molar absorptivity but it has poor solubility in most organic solvents. We have observed that 1,4-dioxane is a good solvent for mefenamic acid but with low solubility of inactive ingredients in the tablet. Further, high boiling point (b.p. 100º) of dioxane provides accuracy for assay. and 2.5×10 -4 (mol/l). The absorbance of each solution was measured and a calibration curve was plotted using the UV Probe software.
Tablet powder equivalent to 0.0603 g (0.25 mmol) of mefenamic acid was accurately weighed out into 100 ml standard flask, 75 ml of 1,4-dioxane was added, shaken for 10 min and made up to 100 ml. The solution was allowed to stand for 10 min. A 1.0 ml aliquot of the solution was transferred into 20 ml standard fl ask and made up to the mark. The absorbance of 3 ml of the solution was measured at 353.2 nm, against a blank. The concentration of the solution was determined form the calibration curve. The results obtained are given in Table 1. The assay of six different tablets containing mefenamic acid was within acceptable limits indicating that the procedure is accurate. All the tablets could be estimated with an error less than 0.5%. The inactive ingredients present in the tablets did not interfere with the analysis. Meftal Forte contains paracetamol as an additional active ingredient but did not interfere with the assay of mefenamic acid since the λ max. for paracetamol is 289 nm. 
